These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10960846)

  • 1. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
    Khan SR; Denmeade SR
    Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
    Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
    J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
    Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
    Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer.
    DiPaola RS; Rinehart J; Nemunaitis J; Ebbinghaus S; Rubin E; Capanna T; Ciardella M; Doyle-Lindrud S; Goodwin S; Fontaine M; Adams N; Williams A; Schwartz M; Winchell G; Wickersham K; Deutsch P; Yao SL
    J Clin Oncol; 2002 Apr; 20(7):1874-9. PubMed ID: 11919247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
    Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
    J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design.
    Pereira SGT; Hudoklin S; Kreft ME; Kostevsek N; Stuart MCA; Al-Jamal WT
    Mol Pharm; 2019 Apr; 16(4):1573-1585. PubMed ID: 30802065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
    Denmeade SR; Nagy A; Gao J; Lilja H; Schally AV; Isaacs JT
    Cancer Res; 1998 Jun; 58(12):2537-40. PubMed ID: 9635575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.
    DeFeo-Jones D; Brady SF; Feng DM; Wong BK; Bolyar T; Haskell K; Kiefer DM; Leander K; McAvoy E; Lumma P; Pawluczyk JM; Wai J; Motzel SL; Keenan K; Van Zwieten M; Lin JH; Garsky VM; Freidinger R; Oliff A; Jones RE
    Mol Cancer Ther; 2002 May; 1(7):451-9. PubMed ID: 12479263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy.
    Pereira S; Ma G; Na L; Hudoklin S; Kreft ME; Kostevsek N; Al-Jamal WT
    Acta Biomater; 2022 Mar; 140():530-546. PubMed ID: 34954416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
    Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo.
    DeFeo-Jones D; Garsky VM; Wong BK; Feng DM; Bolyar T; Haskell K; Kiefer DM; Leander K; McAvoy E; Lumma P; Wai J; Senderak ET; Motzel SL; Keenan K; Van Zwieten M; Lin JH; Freidinger R; Huff J; Oliff A; Jones RE
    Nat Med; 2000 Nov; 6(11):1248-52. PubMed ID: 11062536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
    Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Abu Ajaj K; Unger C; Warnecke A; Saleem T; El-Melegy N; Madkor H; Kratz F
    Eur J Cancer; 2010 Dec; 46(18):3434-44. PubMed ID: 20933385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
    Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
    Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
    Akinboye ES; Rosen MD; Bakare O; Denmeade SR
    Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
    Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
    Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
    van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
    Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.
    Williams SA; Merchant RF; Garrett-Mayer E; Isaacs JT; Buckley JT; Denmeade SR
    J Natl Cancer Inst; 2007 Mar; 99(5):376-85. PubMed ID: 17341729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
    Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Tsurumi C; Abu Ajaj K; Warnecke A; Unger C; Saleem T; Kratz F
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):14-21. PubMed ID: 21042336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.